A Review of Papillary Renal Cell Carcinoma and MET Inhibitors

 Papillary renal cell carcinoma (PRCC) is a subtype of renal cell carcinoma (RCC) accounting for approximately 15–20% of cases and further divided into Type 1 and Type 2. Type 1 PRCC tends to have more alterations in the MET tyrosine kinase receptor than Type 2 PRCC. Treatment for RCC patients is ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Rhoades Smith, Katherine Emilie, Bilen, Mehmet Asim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918905/
https://www.ncbi.nlm.nih.gov/pubmed/31867475
http://dx.doi.org/10.3233/KCA-190058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918905/
https://www.ncbi.nlm.nih.gov/pubmed/31867475
http://dx.doi.org/10.3233/KCA-190058

Ejemplares similares